Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "Sochoń, J." wg kryterium: Autor


Wyświetlanie 1-3 z 3
Tytuł:
Granulocyte colony-stimulating factor therapy for facioscapulohumeral dystrophy: a case report
Autorzy:
Sienkiewicz, D.
Kułak, W.
Okurowska-Zawada, B.
Paszko-Patej, G.
Wojtkowski, J.
Dmitruk, E.
Okulczyk, K.
Sochoń, K.
Kalinowska, A.
Żak, J.
Pogorzelski, R.
Powiązania:
https://bibliotekanauki.pl/articles/1918329.pdf
Data publikacji:
2016
Wydawca:
Uniwersytet Medyczny w Białymstoku
Tematy:
Facioscapulohumeral dystrophy
granulocyte colony-stimulating factor
muscle strength
Opis:
We examined the safety and effectiveness of a low dose of analog granulocyte-colony stimulating factor in a 15-year-old boy with facioscapulohumeral dystrophy. The onset of disease was noted at 12 years of age. The physical examination noted general muscle atrophy more pronounced at left side of the body. He was able to walk 300 meters within 6 minute walk test. Granulocyte colony-stimulating factor 5 μg/kg was given subcutaneously daily for 5 days/month for 1, 2, 3, 6 and 12 months. Clinical examination, laboratory tests including blood, biochemical tests, and CD34+ cells were performed. A significant increase of muscle strength in the lower and upper limbs between baseline, and after 3 months of treatment, after 6, and after 12 months was found. He was able to walk 480 meters within 6 minutes after 12 months. Electromyography demonstrated increase of amplitude in the examined in upper and lower limbs after six months compared to baseline. Leukocyte levels remained below 25000/μL. CD34+ increased significantly at day 5 of granulocyte colony-stimulating factor admini-stration. It was safe and well tolerated by the patient. A significant increase in muscle strength in this patient with facioscapulohumeral dystrophy after 3 months of treatment, after 6, and after 12 months since the first treatment course was completed may indicate beneficial effects of granulocyte colony-stimulating factor in this disorder.
Źródło:
Progress in Health Sciences; 2016, 6(2); 175-177
2083-1617
Pojawia się w:
Progress in Health Sciences
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Effects of granulocyte colony-stimulating factor therapy for osteogenesis imperfecta: a case report
Autorzy:
Paszko-Patej, G.
Sienkiewicz, D.
Kułak, W.
Okurowska-Zawada, B.
Wojtkowski, J.
Kalinowska, A.
Okulczyk, K.
Sochoń, K.
Dmitruk, E.
Mirska, A.
Powiązania:
https://bibliotekanauki.pl/articles/1918408.pdf
Data publikacji:
2017
Wydawca:
Uniwersytet Medyczny w Białymstoku
Tematy:
Osteogenesis imperfecta
granulocyte colony-stimulating factor
muscle strength
Opis:
Introduction: Osteogenesis imperfecta (OI) is a genetic disorder of increased bone fragility and low bone mass. OI type IV. Materials and methods: We examined the safety and effectiveness of a low dose of analog granulocyte colony-stimulating factor (G-CSF) in a 15-year-old girl OI type IV. G-CSF 5 μg/kg was given subcutaneously, for 5 days/month for 3, 6 and 12 months. Laboratory tests, including blood, biochemical tests were performed, in addition to clinical examination.Results: Clinical examination revealed an increase of muscle strength in the upper and lower limbs between base line and day 6 and 12 months. We found no serious adverse events. Leukocyte levels remained below 38,000/μL. Low dose G-CSF was safe and well tolerated by the patient. Conclusions: A significant increase in muscle strength in this patient may indicate beneficial effects of G-CSF factor in this disorder. These results are inspiring and warrant further studies.
Źródło:
Progress in Health Sciences; 2017, 7(1); 205-208
2083-1617
Pojawia się w:
Progress in Health Sciences
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Effects of granulocyte colony-stimulating factor treatment in children and patients with cerebral palsy: a preliminary report
Autorzy:
Paszko-Patej, G.
Kułak, W.
Okurowska-Zawada, B.
Sienkiewicz, D.
Wojtkowski, J.
Sochoń, K.
Kalinowska, A.
Okulczyk, K.
Topór, E.
Mirska, A.
Powiązania:
https://bibliotekanauki.pl/articles/1918403.pdf
Data publikacji:
2017
Wydawca:
Uniwersytet Medyczny w Białymstoku
Tematy:
Granulocyte colony-stimulating factor
children
cerebral palsy
Opis:
Introduction: Recent reports have revealed that neuroinflammation and apoptosis in brains affected by cerebral palsy could be therapeutic targets. Granulocyte colony-stimulating factor (G-CSF) exerts anti-inflammatory and antiapoptosis effects and stimulates the proliferation of neural stem and progenitor cells in the brain. Purpose: To assess the efficacy and safety of G-CSF treatment in children and adolescents with CP. Materials and methods: Six patients with spastic tetraplegia CP aged 3-15 years were enrolled in this study. Five patients had GMFCS (Gross Motor Function Classification System) level at V, three children had epilepsy, and three had severe mental retardation. We used the gross motor function measure-66 (GMFM-66) to assess motor function.GCSF (5μg/kg/body/day) was administered subcutaneously for five consecutive days during the four months. The parents also evaluated the physical and mental development of their children. Results: We observed improvement in motor function in patients with CP on the GMFM-66 scale. Parents reported improvement in behavior, speech development, and a decrease in spasticity in children with CP. G-CSF therapy was well-tolerated. No side effects were observed during the study. Conclusions: Our preliminary report suggests that G-CSF treatment improves motor and mental function in patients with CP. Further studies are needed to confirm these observations
Źródło:
Progress in Health Sciences; 2017, 7(1); 78-82
2083-1617
Pojawia się w:
Progress in Health Sciences
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-3 z 3

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies